Tonix Pharmaceuticals Holding CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 4.9% of Tonix Pharmaceuticals Holding Corp. common stock, including shares issuable upon warrant exercise.
NASDAQ
AQR Capital Management, through its subsidiaries, has reported beneficial ownership of 5.54% of Tonix Pharmaceuticals Holding Corp.'s common stock as of June 30, 2026.
NASDAQ
Millennium Management LLC and affiliates have filed a Schedule 13G reporting a 5.6% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp.
NASDAQ
Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Tonix Pharmaceuticals Holding Corp. common stock.
NASDAQ
The Vanguard Group's beneficial ownership in Tonix Pharmaceuticals Holding Corp. has dropped to 0% following an internal realignment.
NASDAQ
The Vanguard Group has reported a 5.02% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. as of December 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Maintains 6.7% Stake in Tonix Pharma
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a continued 6.7% passive ownership stake in Tonix Pharmaceuticals Holding Corp. as of December 31, 2025.
NASDAQ
SCHEDULE 13G: Point72 Discloses 9.2% Stake in Tonix Pharma
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly disclosed a 9.2% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp.
NASDAQ
The Vanguard Group has reported a 6.35% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. common stock.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Stake in Tonix Pharma to 7.8%
BlackRock, Inc. has reported a 7.8% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. common stock as of September 30, 2025.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.7% of Tonix Pharmaceuticals Holding Corp.'s common stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: L1 Capital Global Opportunities Master Fund Divests Entire Stake in Tonix Pharmaceuticals
L1 Capital Global Opportunities Master Fund, Ltd. has reported a complete divestment of its beneficial ownership in Tonix Pharmaceuticals Holding Corp., reducing its stake from 432,187 shares to zero.
NASDAQ
Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly disclosed a passive beneficial ownership of 0.7% of Tonix Pharmaceuticals Holding Corp.'s common stock as of December 31, 2024.